Category Archives: Affordable Care Act

ACA Supreme Court Deliberations and Any Impact on Biosimilars?

If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down

Thoughtfully Addressing U.S. Healthcare Trends

As costs for health insurance continue to increase, it is time to identify and address the root causes and rethink the model of delivering health insurance

Dr. Vogenberg on Regulatory and Legislative Changes Effect on Healthcare, P&T Committees

AMI founding partner Dr. Randy Vogenberg recently co-authored an article for Pharmacy & Therapeutics (P&T)’s January 2018 issue entitled “Regulatory Change Versus Legislation Impacting Health Care Decisions and Delivery”.  The article explores high-level trends of the Trump administration’s policy, legislative agenda, and regulations, focusing on FDA policies that may affect drug prices and relaxation of the […]

Section 1332 Opportunity for Pharmaceutical Manufacturers

Section 1332 Opportunity for Pharmaceutical Manufacturers – by Gregory Judd, CEBS   A funny thing happened while pharmaceutical manufacturers were going through wrenching strategic and organizational changes during the past 6 or 7 years. The Affordable Care Act. Ok, so ACA is not all THAT funny. But it IS big, and has exerted a sort of […]

Key Strategic Trends that Impact Healthcare Decision-Making and Stakeholder Roles in the New Marketplace

By John Santilli, MBA, and F. Randy Vogenberg, PhD, RPh After the passage of the Affordable Care Act (ACA) in 2010, market changes beyond those already in play began to emerge. Traditional roles, responsibilities, and authority could now be tested or altered as a result of some sections of the ACA. One result is that […]